… inclusion criteria: 278 (35.8%) obese patients treated with DOACs, 266 (34.2%) non-obese …
patients as defined herein. However, since most of our patients were treated with rivaroxaban…

… weighing 50 kg, 70–80 kg, or > 120 kg were given a single 10 mg dose of rivaroxaban. In …
achieve a therapeutic International Normalized Ratios (INR) compared to non-obese patients (…

… We used network meta-analysis as it allows for the simultaneous comparison of multiple
treatments (apixaban, dabigatran, rivaroxaban, and warfarin) within the same analysis. This …

… in these patients; as a consequence, the issue of whether the newer … therapies in obese
patients provide a protection from thromboembolic events similar to non-obese patients …

… the use of DOACs in non-obese patients with cancer-related … oral anticoagulants in patients
with obesity for treatment and … versus non-obese patients receiving rivaroxaban therapy: An …

… [51] All patients in this study received the appropriate rivaroxaban dose of 15 mg daily. In …
in patients receiving VTE treatment with rivaroxaban 20 mg daily.[78] There were 105 patients …

… /m 2 ) patients who were more likely than non-obese patients to be … patients with VTE
receiving rivaroxaban had similar risks of recurrent VTE and major bleeding compared with patients …

… In a study of otherwise healthy obese and non-obese individuals administered enoxaparin
1.5 … In the dose finding study of rivaroxaban, it was noted that rivaroxaban concentrations did …

… with apixaban and rivaroxaban treatment in morbidly obese versus non-obese patients …
In this analysis of 291 patients, apixaban and rivaroxaban were not associated with an …

… obese patients than in non-obese patients, 1 but, in a retrospective analysis of the patients
… In both studies no differences in the relative effects of NOACs (rivaroxaban and apixaban, …